ATOMOXETINE HYDROCHLORIDE (atomoxetine) by PharmaIN is attention-deficit/hyperactivity disorder (adhd) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies. Approved for attention-deficit/hyperactivity disorder (adhd). First approved in 2021.
Drug data last refreshed 18h ago
Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies.
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)
Trial of AD113 and Atomoxetine in OSA Patients With Hypertension
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Atomoxetine PBPK-PD Clinical Study
Worked on ATOMOXETINE HYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.